Friday 30 September 2016

Gilead's Growth Tonic Is Elusive, May Have Side Effects

The biotech company’s deliberate approach to deal making has frustrated investors, but it could still pay off.

from WSJ.com: Markets http://ift.tt/2cH4nua
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)